BioMarin Pharmaceutical Inc.

BMRNNASDAQHealthcare● Active

$56.77

+$0.30(+0.53%)

Market Cap$11.0B

P/E Ratio—

52W High$66.28

52W Low$49.26

Avg Volume2.0M

Open$56.16

Beta0.24

Free Cash Flow Financials Revenue

BioMarin Pharmaceutical Inc. (BMRN) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BMRN · free cash flow · updated Jun 8, 2026

Core FCF metrics

BMRN · FCF · TTM · margin & CAGR

Free cash flow was $725.0M for FY2025 (fiscal year ending 2025-12-31), up 52.5% year-over-year The FCF margin was 22.5%.

FY2025 Free Cash Flow$725.0M▲ +52.5% YoY

Trailing 12M (TTM)$767.1Mtrailing 4 quarters sum

FCF Margin22.5%$725.0M ÷ revenue

3-Year CAGR+136.3%FY2022 → FY2025

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BMRN · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$828.0M(103M)$725.0M▲ +52.5%22.5%

FY2024$572.8M(97M)$475.4M▲ +659.9%16.7%

FY2023$159.3M(97M)$62.6M▲ +13.9%2.6%

FY2022$175.9M(121M)$54.9M▼ 70.4%2.6%

FY2021$304.5M(119M)$185.3M▲ +455.3%10.0%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BMRN · P/FCF · FCF yield · FCF per share

BioMarin Pharmaceutical Inc. (BMRN) trades at a FCF yield of 6.99% and a price-to-free-cash-flow ratio of 14.2x. FCF per share stands at $4.00, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

6.99%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$4.00

TTM FCF ÷ Shares Outstanding

Price / FCF

x14.2

Share Price ÷ FCF per Share

EV / FCF (TTM)

x13.3

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BMRN · cash flow statement · operating / investing / financing

For FY2025, BioMarin Pharmaceutical Inc. generated $828.0M in operating cash flow and spent 103M in capital expenditures, yielding $725.0M in free cash flow.

Operating Activities

+$828.0M

Cash from core business operations

2025-12-31

Investing Activities

−$414.2M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$42.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($828.0M) − |CapEx| (103M) = FCF ($725.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BMRN vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BioMarin Pharmaceutical Inc.YOU

BMRN

$725.0M+52.5%22.5%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BioMarin Pharmaceutical Inc. (BMRN) reported free cash flow of $725.0M for FY2025 (fiscal year ending 2025-12-31), up 52.5% year-over-year. The FCF margin was 22.5%.

Based on available data, BioMarin Pharmaceutical Inc. has maintained positive free cash flow for at least 5 fiscal year(s). FCF peaked at $725.0M in FY2025.

BioMarin Pharmaceutical Inc.'s FCF yield is 6.99% and price-to-FCF ratio is 14.2x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BMRN free cash flow · 8 questions

BioMarin Pharmaceutical Inc. free cash flow was $725.0M for FY2025, up 52.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $767.1M.

BMRN free cash flowBMRN FCFBMRN FCF 2025BMRN free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BioMarin Pharmaceutical Inc. · BioMarin Pharmaceutical Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026